Navigation Links
Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
Date:9/30/2013

SAN FRANCISCO, Sept. 30, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) reported today that AstraZeneca announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist, which has been specifically designed for the treatment of opioid-induced constipation (OIC) for adult patients 18 years and older, including patients with inadequate response to laxatives.

The MAA filing was based on comprehensive data from the core Phase III KODIAC programme, comprised of four clinical trials designed to investigate the safety and efficacy of naloxegol for the treatment of OIC. Two pivotal Phase III studies, KODIAC-04 (n=652) and KODIAC-05 (n=700), both 12-week, multicentre, randomised, double blind, placebo-controlled pivotal trials evaluated 12.5 mg and 25 mg doses of naloxegol, administered once-daily. KODIAC-07 was a 12-week safety extension of KODIAC-04, and KODIAC-08 (n= 534) was an open-label, randomised, 52-week, long-term safety trial.

Naloxegol has the potential to be the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for patients with OIC. Naloxegol was developed using Nektar's oral small molecule polymer conjugate technology.

Naloxegol is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics. Under the terms of the recently amended License Agreement, AstraZeneca will pay Nektar a $25 million milestone within five business days of acceptance of the MAA by the EMA.

NOTES TO EDITORS

About Opioid-Induced Constipation
OIC is a condition caused by prescription opioid pain medicines. Opioids bind to specific proteins called opioid receptors. When the opioids bind to certain opioid receptors in the gastrointestinal (GI) tract, constipation may occur. Opioid-induced constipation is a result of increased fluid absorption and lower GI motility due to opioid receptor binding in the gastrointestinal tract.

Globally, approximately 40–50% (28-35 million) of patients taking opioids for long-term pain develop opioid-induced constipation. About 40–50% (11-18 million) of those OIC sufferers achieve the desired treatment outcomes with current options that include over-the-counter and prescription laxatives.

About Nektar

Nektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, has completed Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare to treat patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
2. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
3. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
4. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
5. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
6. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
10. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
11. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... DIEGO and BLOOMINGTON, Minn. ... Inc. (NASDAQ: IMMY ) ("Imprimis"), an ... Precision Lens ("Precision Lens"), today announced the signing ... the agreement, Precision Lens will deploy a dedicated ... select geographies in the U.S., primarily focused in ...
(Date:4/18/2017)... , April 18, 2017 Research and ... the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast ... ... molecular imaging equipment revenues as well as growth in the ... will provide value to market participants that design and manufacture ...
(Date:4/18/2017)... 2017 Recursion Pharmaceuticals , an emerging ... learning techniques to discover treatments for rare genetic diseases, ... as vice president of biology. Chong joins the ... Belgium , where as a principal ... high-dimensional biological approaches to the small molecule lead discovery ...
Breaking Medicine Technology:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... Health held the much anticipated Regional Primary Care Spring Symposium on April 1, ... the local medical community, offering physicians and healthcare providers an opportunity to learn ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... is seeking candidates to serve on its Accreditation and Standards Committees to ... ultimate mission is improving image quality and reducing patient radiation dose,” reports ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a home care ... Utah (APCUT) and has appointed Rex Wheeler as its new Director of Business Development. ... agency and our ability to provide quality care to the community,” said Tammara Brown, ...
(Date:4/21/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, wrote an open letter this week ... peace plan. Yisrayl says war has never brought peace and he knows the only solution ... , Yisrayl says war drums are beating all over the media and the tensions among ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... During April ... Augusta, Georgia. , This festival offers entertainment for everyone — from the avid ... Garden Festival is a very high quality event held in a grand venue, and ...
Breaking Medicine News(10 mins):